Get the Stockscreener App
2.44
2.52%
0.06
After Hours:
2.38
-0.06
-2.46%
Annexon Inc stock is traded at $2.44, with a volume of 2.66M.
It is up +2.52% in the last 24 hours and down -2.40% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$2.38
Open:
$2.45
24h Volume:
2.66M
Relative Volume:
1.83
Market Cap:
$267.70M
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-1.3785
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
+3.39%
1M Performance:
-2.40%
6M Performance:
-20.52%
1Y Performance:
-59.20%
1-Day Range:
$2.35
$2.575
1-Week Range:
$2.31
$2.71
52-Week Range:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650)-822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.44 | 261.12M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon Biosciences Reports Q2 2025 Financial Results - TipRanks
Strategies to average down on Annexon Inc.Earnings Trend Report & Daily Profit Maximizing Tips - Newser
Regression Model Predicts Rangebound Movement in Annexon Inc.2025 Geopolitical Influence & Risk Controlled Stock Alerts - sundaytimes.kr
Annexon's Path to Commercialization: Assessing Clinical Milestones and Financial Viability in a High-Risk, High-Reward Biotech Play - AInvest
Annexon Narrows Loss in Fiscal Q2 - The Globe and Mail
Annexon Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Annexon's Strategic Momentum in 2025: Near-Term Catalysts and Long-Term Value Creation - AInvest
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewswire
How Annexon Inc. stock performs during market volatilityAnalyst Downgrade & Safe Capital Growth Plans - Newser
What makes Annexon Inc. stock price move sharplyPortfolio Update Summary & Stepwise Swing Trade Plans - Newser
Momentum divergence signals in Annexon Inc. chartQuarterly Portfolio Report & Consistent Growth Equity Picks - Newser
Can Annexon Inc. lead its sector in growthMarket Risk Summary & Weekly Top Gainers Trade List - 선데이타임즈
Will Annexon Inc. rebound enough to break evenJuly 2025 Reactions & Daily Profit Focused Stock Screening - Newser
Price momentum metrics for Annexon Inc. explainedShare Buyback & Free Verified High Yield Trade Plans - Newser
Is Annexon Inc. stock risky to hold nowCEO Change & Long Hold Capital Preservation Tips - newsyoung.net
Can Annexon Inc. recover in the next quarter2025 Winners & Losers & AI Driven Stock Reports - Newser
Signal strength of Annexon Inc. stock in tech scannersSmart Trend Analysis With Buy Point Cues - Newser
Is Annexon Inc. stock a growth or value playFree Stock Market Watch With Alerts - Newser
Applying sector rotation models to Annexon Inc.Oversold Opportunity Scanner with RSI Data - Newser
How Interest Rate Changes Impact Annexon Inc. Stock PerformancePredictive Screener for Daily Trade Watch - Newser
Will a bounce in Annexon Inc. offer an exitSteady Return Plan Based on Data Analysis - Newser
Is Annexon Inc. stock trending bullishPredictable Big Profit Stocks - kangso.co.kr
Annexon Inc. Building a Base Near SupportWeekly Watchlist of High Movers Released - beatles.ru
Annexon, Inc. (NASDAQ:ANNX) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Trend analysis for Annexon Inc. this weekDay Trading Plan with Entry Risk Management - Newser
How to forecast Annexon Inc. trends using time seriesSafe Entry Screening with Data Backed Analysis - Newser
Combining price and volume data for Annexon Inc.Free ROI Driven Equity Selection With Safety - Newser
Momentum Screeners Rank Annexon Inc. in Top 5 TodaySwing Trading Entry Signals Suggest Opportunity Zone - metal.it
What is Annexon Inc. s 5 year growth outlookElite Portfolio Components - mustnews.co.kr
Annexon ANNX 2025Q2 Earnings Preview Downside Expected Amid Weak Eurozone Economic Sentiment - AInvest
Will Annexon Inc. stock go up soonIntraday Price Forecast Using Volume Models - Newser
Annexon, Inc. Announces vonaprument's Selection for EMA's PDC Pilot Program, Paving the Way for Potential Dry AMD Treatment Approval - Quiver Quantitative
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy - The Manila Times
Breakthrough Eye Drug Among 20 Selected for EMA Fast Track: Could Be First Dry AMD Treatment in Europe - Stock Titan
Annexon, Inc. (NASDAQ:ANNX) Shares Sold by TD Asset Management Inc - Defense World
What makes Annexon Inc. stock attractive to long term investorsHigh Growth Low Risk Stock Selection Gets Analyst Nod - beatles.ru
What is the dividend policy of Annexon Inc. stockDiscover the fastest growing stocks today - Jammu Links News
Why is Annexon Inc. stock attracting strong analyst attentionInvest smarter with expert stock picks - Jammu Links News
Should I hold or sell Annexon Inc. stock in 2025Identify undervalued stocks ready to soar - Jammu Links News
Does Annexon Inc. stock perform well during market downturnsOver 200% growth - Jammu Links News
Is Annexon Inc. a growth stock or a value stockCapitalize on momentum-driven investment opportunities - Jammu Links News
What is Annexon Inc. company’s growth strategyAccelerated profit realization - Jammu Links News
When is Annexon Inc. stock expected to show significant growthExtraordinary earning power - Jammu Links News
What markets is CYCC expanding into Is Annexon Inc. stock a good long term investment option - Jammu Links News
Annexon Inc. Stock Analysis and ForecastSuperior capital gains - Jammu Links News
What are analysts’ price targets for Annexon Inc. in the next 12 monthsBreakthrough wealth creation - Jammu Links News
Is Annexon Inc. a Top Dividend Stock to Watch in 2025Short-Term Profit Alert With Entry Forecast - Newser
Carson William H. buys Annexon (ANNX) shares worth $9,999 By Investing.com - Investing.com Australia
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):